-
Post date
January 18, 2022
-
Posted by
Vishal Toora
-
Posted in
best psychedelics stocks, Cybin Therapeutics, Filament Health, Filament Health (FH.NE), Mushrooms, Mushshroom, PSIL, Psychedelic Stocks, Psychedelics, PSYK, shroom-stocks, shrooms, Today's Analysis
-
Post date
August 23, 2021
-
Posted by
Vishal Toora
-
Posted in
2021 psychedelic stocks, best psychedelic stocks, Canadian shroom-stocks, Featured Content, Mushrooms, mushshrooms, Psychedelics, shroom-stocks, shrooms, Toora
-
Post date
June 28, 2021
-
Posted by
Piers Eaton
-
Posted in
Adelia Therapeutics, Biotech, Cash on had, Cash on hand, cybin, CYBN.NE, Eaton, financial results, Health Science, Milestones, mushroom, Mushrooms, psilocybin, Psychedelics, research, Science, Scribes, shrooms
-
Post date
June 16, 2021
-
Posted by
Piers Eaton
-
Posted in
CYB004, cybin, CYBN.NE, GAD, Generalized Anxiety Disorder, Health Science, mental health, Mushroom Moves, Mushrooms, psilocybin, Psychedelics, SAD, Series, shrooms, Social Anxiety Disorder
-
Post date
April 27, 2021
-
Posted by
Lukas Kane
-
Posted in
5 best Canadian Biotechs, Biotech, Biotech collaborations, Bucillamine, Canadian Biotech, cancer treatment, Cannabis, clinical sites, Covid-19 treatment, CRO, CymaBay Therapeutics (CBAY.NASDAQ), Fabio Chianelli, Featured Content, Health Science, Institutional Review Board, Investigational new drug, IRB, Kane, liver disease, massive buying, mushroom, mushroom research, Mushrooms, Novotech, Pharm-Olam LLC, PharmaTher, PharmaTher (PHRM.C), Phase 3 FDA trial, Phase 3 trial, Psychedelics, research, resperitory viral infections, Revive Therapeutics, RVV.C, Scribes, Series, shrooms, stock price surge, undervalued bio tech companies, wealth creation